普瑞眼科
(301239)
| 流通市值：50.70亿 | | | 总市值：53.40亿 |
| 流通股本：1.42亿 | | | 总股本：1.50亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,445,941,857.05 | 1,602,037,256.53 | 820,353,329.11 | 2,797,261,037.47 |
| 营业收入 | 2,445,941,857.05 | 1,602,037,256.53 | 820,353,329.11 | 2,797,261,037.47 |
| 二、营业总成本 | 2,215,728,155.61 | 1,464,529,396.87 | 726,043,058.39 | 2,746,109,913.2 |
| 营业成本 | 1,477,563,866.47 | 975,880,291.49 | 483,224,184.77 | 1,792,714,036.5 |
| 税金及附加 | 4,813,198.8 | 3,083,527.87 | 1,414,255.72 | 6,397,538.12 |
| 销售费用 | 411,261,259.75 | 274,178,408.88 | 137,927,875.45 | 518,364,310.43 |
| 管理费用 | 251,829,506.51 | 164,500,909.42 | 79,589,016.99 | 329,573,589.03 |
| 研发费用 | 7,816,431.82 | 4,916,508.54 | 2,442,210.9 | 10,816,545.79 |
| 财务费用 | 62,443,892.26 | 41,969,750.67 | 21,445,514.56 | 88,243,893.33 |
| 其中:利息费用 | 59,757,549.08 | 38,983,816.23 | 20,128,944.67 | 85,150,529.14 |
| 其中:利息收入 | 1,579,389.4 | 1,269,374.96 | 377,310.29 | 4,201,257.26 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -485,808.22 | -326,630.14 | -725,856.07 | 724,164.39 |
| 加:投资收益 | 2,711,219.07 | 546,358.22 | -316,782.29 | -10,892,876.65 |
| 资产处置收益 | -233,716.97 | -46,603.42 | -46,603.42 | 668.66 |
| 资产减值损失(新) | -1,637,000.28 | -1,072,142.12 | -628,020.14 | -11,357,225.83 |
| 信用减值损失(新) | -57,567.43 | -500,814.97 | -778,902.48 | -1,799,845.98 |
| 其他收益 | 4,816,742.34 | 2,714,322.57 | 2,433,056.8 | 3,248,373.86 |
| 四、营业利润 | 235,327,569.95 | 138,822,349.8 | 94,247,163.12 | 31,074,382.72 |
| 加:营业外收入 | 711,523.09 | 360,485.57 | 303,345.22 | 1,270,620.5 |
| 减:营业外支出 | 13,573,098.66 | 8,418,907.63 | 2,062,438.88 | 19,829,378.14 |
| 五、利润总额 | 222,465,994.38 | 130,763,927.74 | 92,488,069.46 | 12,515,625.08 |
| 减:所得税费用 | 63,633,287.66 | 38,413,320.75 | 19,490,579 | 66,234,455.94 |
| 六、净利润 | 158,832,706.72 | 92,350,606.99 | 72,997,490.46 | -53,718,830.86 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 158,832,706.72 | 92,350,606.99 | 72,997,490.46 | -53,718,830.86 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 151,060,915.52 | 88,108,788.54 | 70,645,328.36 | -60,922,620.1 |
| 少数股东损益 | 7,771,791.2 | 4,241,818.45 | 2,352,162.1 | 7,203,789.24 |
| 扣除非经常损益后的净利润 | 158,869,878.32 | 93,592,851.65 | 70,834,676.76 | -48,206,091.88 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.01 | 0.59 | 0.47 | -0.41 |
| (二)稀释每股收益 | 1.01 | 0.59 | 0.47 | -0.41 |
| 八、其他综合收益 | - | - | - | 29,078.28 |
| 归属于母公司股东的其他综合收益 | - | - | - | 29,078.28 |
| 九、综合收益总额 | 158,832,706.72 | 92,350,606.99 | 72,997,490.46 | -53,689,752.58 |
| 归属于母公司股东的综合收益总额 | 151,060,915.52 | 88,108,788.54 | 70,645,328.36 | -60,893,541.82 |
| 归属于少数股东的综合收益总额 | 7,771,791.2 | 4,241,818.45 | 2,352,162.1 | 7,203,789.24 |
| 公告日期 | 2026-10-28 | 2026-08-29 | 2026-04-28 | 2026-04-28 |
| 审计意见(境内) | | | | 标准无保留意见 |